Visen Pharma Reports 182-Week PaTHway China Phase 3 Data for Palopegteriparatide

Visen Pharma reported 182-week long-term data from the phase 3 PaTHway China trial of palopegteriparatide. 95.6% of patients remained off conventional therapy, mean eGFR rose 13.6 mL/min/1.73 m² from baseline, and 75.7% of patients had an eGFR increase of at least 5 mL/min/1.73 m².